spacer
home > ebr > spring 2002 > prevention and cure - intellectual property due diligence and warranties in biotechnology and pharmaceutical technology transfer agreements
PUBLICATIONS
European Biopharmaceutical Review

Prevention and Cure - Intellectual Property Due Diligence and Warranties in Biotechnology and Pharmaceutical Technology Transfer Agreements

Part one of this article, which appeared in the last edition of EBR (1), was concerned with the function and importance of intellectual property due diligence in the context of biotechnology and pharmaceutical technology transfer agreements. Having looked at this crucial aspect of the pre-contract process, this second part of the series focuses on the closely related topic of contractual warranties and considers some 'frequently asked questions'.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Daniel Pavin, a Solicitor Specialising in Intellectual Property and Information Technology Law with Taylor Joynson Garrett

Daniel Pavin is a Solicitor specialising in intellectual property and information technology law. Daniel advises a wide range of clients, and has a particular focus on clients in the pharmaceutical, biotechnology and information technology sectors. He has a Diploma in Intellectual Property Law and Practice from Bristol University, UK.

Daniel has a degree from Cambridge University in Computer Science and Physics and worked as a Computer Programmer before qualifying as a Solicitor.

spacer
Daniel Pavin
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Destiny Pharma appoints MedPharm to develop new XF-platform drug formulations

Destiny Pharma, a clinical stage biotechnology company focused on the development of novel antimicrobial drugs, is pleased to announce that it has appointed MedPharm as its expert partner to develop new topical formulations of the Company’s novel XF-platform compounds. These new treatments for dermal and ocular infections are part of its second clinical programme to address the global problem of anti-microbial resistance (AMR). MedPharm is a world leading contract provider of topical and transdermal product design and formulation development services using sophisticated in vitro models to de-risk development programmes.
More info >>

White Papers

Utilising Big Data to Produce Faster and Cheaper Clinical Research

Medical Research Network (MRN) Limited

Recruitment and retention of patients remains the major challenge to ensuring trials run as fast as possible and give them the statistical power they are designed to produce. This is not just about getting better any more - but about stopping the deterioration of these metrics in modern clinical trials.
More info >>

 
Industry Events

CPhI & P-MEC India

26-28 November 2019, India Expo Centre, Greater Noida, Delhi NCR, India

As the pharma industry looks increasingly towards India for high quality, low cost pharma solutions, CPhI & P-MEC India is the ideal event for companies wanting to pick up on the latest trends and innovations the market has to offer. At CPhI & P-MEC India, you will meet the movers and shakers from India's pharma machinery, technology and ingredients industries, giving you a competitive advantage that will help grow your business.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement